FILE:BDX/BDX-8K-20071120150902.txt.gz
EVENTS:	Entry into a Material Definitive Agreement	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Entry into a Material Definitive Agreement
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
 
ITEM 8.01
OTHER EVENTS.
        On November 20, 2007, BD issued a press release announcing the declaration of a quarterly dividend. A copy of the press release is attached hereto as Exhibit 99.1.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS.
 
 
        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 20, 2007
 

EXHIBIT 99.1
 
1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com
 
 
 
 
 
 
 
Contacts:
Colleen T. White, Corporate Communications  201-847-5369
Patricia A. Spinella, Investor Relations  201-847-5453
 
 
BD BOARD DECLARES DIVIDEND
 
Franklin Lakes, NJ (November 20, 2007)
 The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 28.5 cents per common share, an increase of 4 cents per share, or 16.3%, from the previous quarter. The dividend will be payable on January 2, 2008 to holders of record on December 12, 2007. At the current rate, the annual dividend for fiscal 2008 would be $1.14 per share.
 
"This marks the 35 consecutive year that BD has increased its dividend. We are committed to a very strong return of cash to our shareholders," said Edward J. Ludwig, BD Chairman, President and Chief Executive Officer.
th
 
About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
 
***
 
 


